AbbVie to Buy Apogee Therapeutics for $10.9B
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, with Investor's Business Daily framing the deal as AbbVie going 'on the offensive'
- Apogee is an immunology-focused company whose lead prospect targets eczema, per Fierce Biotech's framing of the buyout
Why it matters: At $10.9 billion, AbbVie is making a major immunology acquisition anchored by Apogee's eczema prospect. Coverage across WSJ, IBD, and Fierce Biotech frames this as an aggressive strategic move, and the truncated Motley Fool/investor headline signals investors are now weighing how the price tag affects AbbVie's stock.
Ask SkimNews
